Highlights
• Evidence from four randomized controlled trials suggests the effect of riboflavin on blood pressure lowering is very uncertain.
• Mean differences for systolic and diastolic blood pressure were modest and not clinically significant.
• Trials were small, heterogeneous, and at high risk of bias.
• Future well-powered, genotype-specific studies are needed to confirm or refute the potential role of riboflavin in managing hypertension.
